Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).

Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models.

Methods: To establish dose and tolerability of elimusertib with FOLFIRI, a Bayesian Optimal Interval trial design was pursued.

Current developments in T-cell receptor therapy for Acute Myeloid Leukaemia.

T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed towards acute myeloid leukaemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T-cells targeting single surface antigens have shown remarkable efficacy for B-cell lymphoblastic leukaemia, lymphomas and multiple myeloma. However, AML presents formidable obstacles to the effectiveness of CAR T-cells due to the widespread expression of heterogenous leukaemia immunophenotypes and surface antigen targets additionally present on normal myeloid cells.

Influence of C/N ratio & double helical ribbon (DHR) impeller on microbial granulation in anaerobic co-digestion (AnCo-D) of industrial effluents.

The present study demonstrates the significance of the C/N ratio and double helical ribbon (DHR) impeller in the anaerobic co-digestion (AnCo-D) of sugar refining process (SRP) effluent and molasses-based distillery spent wash (DSW) for improved biogas production. Both SRP & DSW were mixed in different percentages to achieve an optimum C/N ratio. Further biomethane potential analysis of mixed feeds with different C/N ratios was performed.

Combining supervised and unsupervised analyses to quantify behavioral phenotypes and validate therapeutic efficacy in a triple transgenic mouse model of Alzheimer's disease.

Behavioral testing is an essential tool for evaluating cognitive function and dysfunction in preclinical research models. This is of special importance in the study of neurological disorders such as Alzheimer's disease. However, the reproducibility of classic behavioral assays is frequently compromised by interstudy variation, leading to ambiguous conclusions about the behavioral markers characterizing the disease.